Hong Kong, 12 November 2026 – BeOne Medicines Ltd. (BeOne) disclosed that its Board’s compensation committee approved the issuance of 15,351 restricted share units (RSUs) on 9 November 2026 under the company’s 2016 Share Option and Incentive Plan.
The newly granted RSUs correspond to 199,563 ordinary shares, representing approximately 0.01% of BeOne’s total issued share capital on the announcement date. A total of 173 employees received the awards; none of the grantees is a director, chief executive, substantial shareholder, related-party participant, or service provider whose allocation would breach any Hong Kong Listing Rule thresholds.
Each RSU was granted at nil consideration. The closing price of BeOne’s American Depositary Shares (ADSs) on the grant date was US$417.33 per ADS (about HK$251.68 per ordinary share). Upon vesting, the grants will deliver 15,351 new ADSs, each representing 13 ordinary shares.
Vesting Schedule • 25% of each award vests on every anniversary of the last trading day of the month following the individual grantee’s employment start date, over four years. • Six non-senior-management grantees will see first-tranche vesting in under 12 months; however, their total vesting and holding period exceeds 12 months. • Certain awards carry accelerated vesting provisions in the event of termination or change-in-control.
The RSUs carry no performance conditions or clawback provisions, aligning with BeOne’s prevailing compensation practices. Following this issuance, 113.72 million ordinary shares remain available for future equity awards under the 2016 plan, including 23.10 million reserved under the consultant sub-limit.
BeOne stated that the equity incentive program enhances flexibility in rewarding and retaining talent, thereby supporting long-term corporate objectives.
Comments